In an era of multimodality cardiac imaging, echocardiography remains the gold standard for the evaluation of valvular and periprosthetic masses.

et al. Adenosine versus regadenosoncomparative evaluation inmyocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645–58. 17. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis fromthe ADVANCE MPI 2 trial. J Am Coll Cardiol Img 2009; 2:959–68. 18. Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. J Am Coll Cardiol Img 2012;5: 1014–21. 19. Paoletti E, Cannella G. Left ventricular hypertrophy in chronic kidney disease. G Ital Nefrol 2006;23:560–8. 20. Bhatti S, Hakeem A, Dillie KS, Cook JR, Chang SM. Prevalence, prognosis, and therapeutic implications of unrecognized left ventricular systolic dysfunction in patients with anemia and chronic kidney disease. Congest Heart Fail 2010;16:271–7. 21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72.